U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Unresectable Lung Non-Small Cell Squamous Carcinoma

MedGen UID:
1769067
•Concept ID:
C5419211
•
Neoplastic Process

Definition

Lung non-small cell squamous carcinoma that is not amenable to surgical resection. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVUnresectable Lung Non-Small Cell Squamous Carcinoma

Professional guidelines

PubMed

Role of CTLA Inhibition in Management of Non-Small Cell Lung Cancer.
Kerrigan K, Puri S
Curr Oncol Rep 2022 Jan;24(1):113-123. Epub 2022 Jan 20 doi: 10.1007/s11912-021-01164-1. PMID: 35060001
Immunotherapy Alone or in Combination with Chemotherapy as First-Line Treatment of Non-Small Cell Lung Cancer.
Saxena P, Singh PK, Malik PS, Singh N
Curr Treat Options Oncol 2020 Jul 27;21(8):69. doi: 10.1007/s11864-020-00768-2. PMID: 32720019
Pemetrexed in first-line treatment of non-small cell lung cancer.
Esteban E, Casillas M, Cassinello A
Cancer Treat Rev 2009 Jun;35(4):364-73. Epub 2009 Mar 6 doi: 10.1016/j.ctrv.2009.02.002. PMID: 19269106

Recent clinical studies

Etiology

Estimating the long-term survival of unresectable stage III non-small cell lung cancer based on cure model analysis.
Wu Y, Jiang Y, Wang W, Zhang T, Li YX, Bi N
Radiother Oncol 2024 Aug;197:110341. Epub 2024 May 23 doi: 10.1016/j.radonc.2024.110341. PMID: 38795813
Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial.
Smit EF, Felip E, Uprety D, Nagasaka M, Nakagawa K, Paz-Ares Rodríguez L, Pacheco JM, Li BT, Planchard D, Baik C, Goto Y, Murakami H, Saltos A, Pereira K, Taguchi A, Cheng Y, Yan Q, Feng W, Tsuchihashi Z, Jänne PA
Lancet Oncol 2024 Apr;25(4):439-454. doi: 10.1016/S1470-2045(24)00064-0. PMID: 38547891
Biomarker Testing in Patients With Unresectable Advanced or Recurrent Non-Small Cell Lung Cancer.
Sakamoto T, Matsubara T, Takahama T, Yokoyama T, Nakamura A, Tokito T, Okamoto T, Akamatsu H, Oki M, Sato Y, Tobino K, Ikeda S, Mori M, Mimura C, Maeno K, Miura S, Harada T, Nishimura K, Hiraoka M, Kenmotsu H, Fujimoto J, Shimokawa M, Yamamoto N, Nakagawa K
JAMA Netw Open 2023 Dec 1;6(12):e2347700. doi: 10.1001/jamanetworkopen.2023.47700. PMID: 38100106Free PMC Article
Molecular testing in stage I-III non-small cell lung cancer: Approaches and challenges.
Aggarwal C, Bubendorf L, Cooper WA, Illei P, Borralho Nunes P, Ong BH, Tsao MS, Yatabe Y, Kerr KM
Lung Cancer 2021 Dec;162:42-53. Epub 2021 Sep 15 doi: 10.1016/j.lungcan.2021.09.003. PMID: 34739853
Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S, Bogart J, Hu C, Forster K, Magliocco A, Kavadi V, Garces YI, Narayan S, Iyengar P, Robinson C, Wynn RB, Koprowski C, Meng J, Beitler J, Gaur R, Curran W Jr, Choy H
Lancet Oncol 2015 Feb;16(2):187-99. Epub 2015 Jan 16 doi: 10.1016/S1470-2045(14)71207-0. PMID: 25601342Free PMC Article

Diagnosis

Biomarker Testing in Patients With Unresectable Advanced or Recurrent Non-Small Cell Lung Cancer.
Sakamoto T, Matsubara T, Takahama T, Yokoyama T, Nakamura A, Tokito T, Okamoto T, Akamatsu H, Oki M, Sato Y, Tobino K, Ikeda S, Mori M, Mimura C, Maeno K, Miura S, Harada T, Nishimura K, Hiraoka M, Kenmotsu H, Fujimoto J, Shimokawa M, Yamamoto N, Nakagawa K
JAMA Netw Open 2023 Dec 1;6(12):e2347700. doi: 10.1001/jamanetworkopen.2023.47700. PMID: 38100106Free PMC Article
Lung adenocarcinoma and squamous cell carcinoma difficult for immunohistochemical diagnosis can be distinguished by lipid profile.
Yamashita T, Takanashi Y, Uebayashi A, Oka M, Mizuno K, Kawase A, Oyama S, Kitamoto T, Kondo M, Omori S, Tao H, Takahashi Y, Sakamoto T, Kahyo T, Sugimura H, Setou M, Shiiya N, Funai K
Sci Rep 2023 Jul 26;13(1):12092. doi: 10.1038/s41598-023-37848-w. PMID: 37495609Free PMC Article
Molecular testing in stage I-III non-small cell lung cancer: Approaches and challenges.
Aggarwal C, Bubendorf L, Cooper WA, Illei P, Borralho Nunes P, Ong BH, Tsao MS, Yatabe Y, Kerr KM
Lung Cancer 2021 Dec;162:42-53. Epub 2021 Sep 15 doi: 10.1016/j.lungcan.2021.09.003. PMID: 34739853
Immunotherapy Alone or in Combination with Chemotherapy as First-Line Treatment of Non-Small Cell Lung Cancer.
Saxena P, Singh PK, Malik PS, Singh N
Curr Treat Options Oncol 2020 Jul 27;21(8):69. doi: 10.1007/s11864-020-00768-2. PMID: 32720019
Deciphering unclassified tumors of non-small-cell lung cancer through radiomics.
Saad M, Choi TS
Comput Biol Med 2017 Dec 1;91:222-230. doi: 10.1016/j.compbiomed.2017.10.029. PMID: 29100116

Therapy

Estimating the long-term survival of unresectable stage III non-small cell lung cancer based on cure model analysis.
Wu Y, Jiang Y, Wang W, Zhang T, Li YX, Bi N
Radiother Oncol 2024 Aug;197:110341. Epub 2024 May 23 doi: 10.1016/j.radonc.2024.110341. PMID: 38795813
Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial.
Smit EF, Felip E, Uprety D, Nagasaka M, Nakagawa K, Paz-Ares Rodríguez L, Pacheco JM, Li BT, Planchard D, Baik C, Goto Y, Murakami H, Saltos A, Pereira K, Taguchi A, Cheng Y, Yan Q, Feng W, Tsuchihashi Z, Jänne PA
Lancet Oncol 2024 Apr;25(4):439-454. doi: 10.1016/S1470-2045(24)00064-0. PMID: 38547891
Molecular testing in stage I-III non-small cell lung cancer: Approaches and challenges.
Aggarwal C, Bubendorf L, Cooper WA, Illei P, Borralho Nunes P, Ong BH, Tsao MS, Yatabe Y, Kerr KM
Lung Cancer 2021 Dec;162:42-53. Epub 2021 Sep 15 doi: 10.1016/j.lungcan.2021.09.003. PMID: 34739853
Chemotherapy for advanced non-small cell lung cancer with a focus on squamous cell carcinoma.
Kuribayashi K, Funaguchi N, Nakano T
J Cancer Res Ther 2016 Apr-Jun;12(2):528-34. doi: 10.4103/0973-1482.174185. PMID: 27461605
Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S, Bogart J, Hu C, Forster K, Magliocco A, Kavadi V, Garces YI, Narayan S, Iyengar P, Robinson C, Wynn RB, Koprowski C, Meng J, Beitler J, Gaur R, Curran W Jr, Choy H
Lancet Oncol 2015 Feb;16(2):187-99. Epub 2015 Jan 16 doi: 10.1016/S1470-2045(14)71207-0. PMID: 25601342Free PMC Article

Prognosis

Estimating the long-term survival of unresectable stage III non-small cell lung cancer based on cure model analysis.
Wu Y, Jiang Y, Wang W, Zhang T, Li YX, Bi N
Radiother Oncol 2024 Aug;197:110341. Epub 2024 May 23 doi: 10.1016/j.radonc.2024.110341. PMID: 38795813
Immune checkpoint inhibitors in esophageal cancer: Clinical development and perspectives.
Nagata Y, Yamamoto S, Kato K
Hum Vaccin Immunother 2022 Nov 30;18(6):2143177. Epub 2022 Nov 14 doi: 10.1080/21645515.2022.2143177. PMID: 36375821Free PMC Article
Computer-assisted subtyping and prognosis for non-small cell lung cancer patients with unresectable tumor.
Saad M, Choi TS
Comput Med Imaging Graph 2018 Jul;67:1-8. Epub 2018 Apr 4 doi: 10.1016/j.compmedimag.2018.04.003. PMID: 29660595
Chemotherapy for advanced non-small cell lung cancer with a focus on squamous cell carcinoma.
Kuribayashi K, Funaguchi N, Nakano T
J Cancer Res Ther 2016 Apr-Jun;12(2):528-34. doi: 10.4103/0973-1482.174185. PMID: 27461605
Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S, Bogart J, Hu C, Forster K, Magliocco A, Kavadi V, Garces YI, Narayan S, Iyengar P, Robinson C, Wynn RB, Koprowski C, Meng J, Beitler J, Gaur R, Curran W Jr, Choy H
Lancet Oncol 2015 Feb;16(2):187-99. Epub 2015 Jan 16 doi: 10.1016/S1470-2045(14)71207-0. PMID: 25601342Free PMC Article

Clinical prediction guides

Estimating the long-term survival of unresectable stage III non-small cell lung cancer based on cure model analysis.
Wu Y, Jiang Y, Wang W, Zhang T, Li YX, Bi N
Radiother Oncol 2024 Aug;197:110341. Epub 2024 May 23 doi: 10.1016/j.radonc.2024.110341. PMID: 38795813
Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial.
Smit EF, Felip E, Uprety D, Nagasaka M, Nakagawa K, Paz-Ares Rodríguez L, Pacheco JM, Li BT, Planchard D, Baik C, Goto Y, Murakami H, Saltos A, Pereira K, Taguchi A, Cheng Y, Yan Q, Feng W, Tsuchihashi Z, Jänne PA
Lancet Oncol 2024 Apr;25(4):439-454. doi: 10.1016/S1470-2045(24)00064-0. PMID: 38547891
Efficacy and surgical safety of sequential surgical resection after pembrolizumab plus chemotherapy for initial unresectable stage IIIB non-small cell lung cancer.
Zheng J, Li Y, Jin C, Ruan K, Sun K, Chen H, Wang M, Zhang S, Zhou J, Zhou J
Lung Cancer 2023 Oct;184:107326. Epub 2023 Aug 11 doi: 10.1016/j.lungcan.2023.107326. PMID: 37579576
Deciphering unclassified tumors of non-small-cell lung cancer through radiomics.
Saad M, Choi TS
Comput Biol Med 2017 Dec 1;91:222-230. doi: 10.1016/j.compbiomed.2017.10.029. PMID: 29100116
COX-2 inhibition and lung cancer.
Sandler AB, Dubinett SM
Semin Oncol 2004 Apr;31(2 Suppl 7):45-52. doi: 10.1053/j.seminoncol.2004.03.045. PMID: 15179623

Recent systematic reviews

Comparison of Concurrent Use of Thoracic Radiation With Either Carboplatin-Paclitaxel or Cisplatin-Etoposide for Patients With Stage III Non-Small-Cell Lung Cancer: A Systematic Review.
Steuer CE, Behera M, Ernani V, Higgins KA, Saba NF, Shin DM, Pakkala S, Pillai RN, Owonikoko TK, Curran WJ, Belani CP, Khuri FR, Ramalingam SS
JAMA Oncol 2017 Aug 1;3(8):1120-1129. doi: 10.1001/jamaoncol.2016.4280. PMID: 27978552
A systematic overview of radiation therapy effects in non-small cell lung cancer.
Sirzén F, Kjellén E, Sörenson S, Cavallin-Ståhl E
Acta Oncol 2003;42(5-6):493-515. doi: 10.1080/02841860310014453. PMID: 14596509

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...